Translational Application of Recombinant Humanized Type III Collagen in Facial Rejuvenation: A Randomized Controlled Trial
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70529 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Zeyu Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Changzhou First People's Hospital, Changzhou, China. Hauptthemen laut MEDLINE: Skin Aging, Rejuvenation, Cosmetic Techniques, Collagen Type III. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Skin aging is a common aesthetic concern that drives the demand for new therapeutic strategies. Lyophilized injectable recombinant humanized type III collagen (rhCol III) is an emerging biomaterial with promising regenerative potential; however, clinical data on its efficacy is limited. This study aimed to evaluate the safety and effectiveness of rhCol III in improving the signs of skin aging.
Methods
A total of 55 participants were enrolled in the study. Those in the treatment group received “water‐light” intradermal injections of the study product alongside their routine skincare regimen. The control group continued with the routine skincare regimen alone. Clinical efficacy was assessed after treatment using VISIA imaging, evaluations by professional dermatologists, and self‐assessments by the participants.
Results
Of the 52 participants who completed the follow‐up (39 in the treatment group, 13 in the control group), scores on the Global Aesthetic Improvement Scale (GAIS) improved significantly in the treatment group at day 90 ± 7 (from 3.17 ± 0.39 to 2.97 ± 0.58), with no notable change in the control group. CMH chi‐square analysis revealed a significant difference in response rates (71.8%; 95% CI: 54.2%–89.4%). VISIA analysis showed significant improvements in spots, wrinkles, texture, and porphyrins (corrected p < 0.00625). Generalized estimating equation (GEE) modeling supported a time‐dependent cumulative effect. The treatment was well tolerated, with stable visual analogue scale (VAS) scores and no serious adverse events.
Conclusion
This preliminary study indicates that lyophilized rhCol III can significantly improve the appearance of the skin and is safe to use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Changzhou First People's Hospital, Changzhou, China.
- Department of Dermatology, The Second Affiliated Hospital of Wannan Medical College, Wuhu, China.
ORCID-Profile: Zeyu Huang, Ruzhi Zhang
Zitieren
APA
Huang, Z., Zhang, R., Sheng, M., Tian, T., Xu, B., Wang, F., & Liu, D. (2025). Translational Application of Recombinant Humanized Type III Collagen in Facial Rejuvenation: A Randomized Controlled Trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70529
Vancouver
Huang Z, Zhang R, Sheng M, Tian T, Xu B, Wang F, et al. Translational Application of Recombinant Humanized Type III Collagen in Facial Rejuvenation: A Randomized Controlled Trial. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70529
BibTeX
@article{Huang2025,
author = {Huang, Zeyu and Zhang, Ruzhi and Sheng, Minmin and Tian, Ting and Xu, Bin and Wang, Fang and Liu, Danmin},
title = {Translational Application of Recombinant Humanized Type III Collagen in Facial Rejuvenation: A Randomized Controlled Trial},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70529}
}
EUVIMED